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1University of Eastern Piedmont, Novara, Italy; 2Saint Andrew
Hospital,Vercelli, Italy
OBJECTIVES: Despite enthusiasm for clinical pathways, they
are so far to be diffused in not academic hospitals and rigorous
evidence to support their beneﬁts in these kind of facilities is
limited. Our purpose was to determine if the use of clinical path-
ways can improve the hospital treatment pattern for heart
failure. METHODS: We performed a multicenter controlled clin-
ical trial with cluster randomization. We tested clinical pathways
in 9 community hospitals in Italy. Hospitals were assigned to
continue conventional management (n = 4) or implement clini-
cal pathway (n = 5), which consisted of a combination of patient
education, appropriate use of practice guidelines, appropriate
consultation and supplies of drugs and ancillary services. A total
of 429 patients (214 cases and 215 controls) with heart failure
presenting to the emergency department at one of the partici-
pating institutions between October 1st 2003 and September
30th 2004 were enrolled. RESULTS: Control and intervention
groups had similar demographics and hearth failure severity 
proﬁles. The intervention group showed a higher compliance to
international guidelines for the treatment of heart failure. We
observed in clinical pathways’ group a signiﬁcant improvement
in the appropriate use of ACE inhibitors (57.94% vs. 40.00%;
p = 0.002), anti-coagulants (58.88% vs. 14.88%; p = 0.001),
beta-blockers (46.73% vs. 10.23%; p = 0.001), digitalis
(66.36% vs. 48.84%; p = 0.002), heparin (50.00% vs. 19.07%;
p = 0.001), nitro-derivates (33.18% vs. 24.19%; p = 0.039) 
and vasodilators (39.25% vs. 3.26%; p = 0.0001). We did not
observe any differences in the use of diuretics (95.33% vs.
95.81%; p = 0.806) and antiplateletes drugs (31.78% vs.
37.67%; p = 0.237). CONCLUSIONS: The overall purpose of
clinical pathways is to improve the process of care by providing
a mechanism to coordinate care and to reduce fragmentation. 
In our study, the implementation of clinical pathways improved
the hospital treatment pattern for heart failure. This suggests 
that clinical pathways have a positive impact on the quality of
care.
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OBJECTIVE: Although it is known that poor medication adher-
ence is a pervasive problem, consequences for the US health care
system are not well understood. Our objective was to generate
quantitative estimates of the health and economic burden of poor
medication adherence. METHODS: We used modeling tech-
niques and data from the published literature to generate annual
estimates of coronary heart disease (CHD) deaths and losses in
net economic beneﬁt attributable to poor adherence with chronic
medications in the US. For CHD mortality, we quantiﬁed the
extent to which poor adherence to antihypertensive, cholesterol-
lowering, and hypoglycemic medications contributes to CHD
deaths. We quantiﬁed losses in net economic beneﬁt attributable
to poor adherence in terms of forgone medical cost offsets and
lost QALYs, taking into account also the counter inﬂuence of
pharmacy costs avoided because poorly adherent patients ﬁll
fewer prescriptions. We assumed that 50% of patients are poorly
adherent (either discontinuing therapy or not complying with
recommended dosing), that the average therapy would have a
cost-effectiveness ratio of $50,000/QALY under full adherence,
and that QALYs are valued at $100,000 in the US (as assumed
in a recent Institute of Medicine report on the cost of the unin-
sured). RESULTS: We estimate that 37,000 CHD deaths annu-
ally (approximately 8% of all CHD mortality in the US) are
attributable to poor adherence with antihypertensive, choles-
terol-lowering, and hypoglycemic medications. We further esti-
mate that losses in net economic beneﬁt attributable to poor
adherence with all chronic medications amount to $138.5 billion
annually (2003 USD), including $51.9 billion in forgone medical
cost offsets and $242.3 billion in lost QALYs, counterbalanced
by $155.8 billion in avoided costs of prescription drugs. These
ﬁndings are sensitive to assumptions regarding the pervasiveness
of poor medication adherence. CONCLUSIONS: The health and
economic consequences of poor medication adherence in the US
are substantial.
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EVALUATING THE DIAGNOSTIC VALIDITY OF
ADMINISTRATIVE CLAIMS DATA FOR COMMON CHRONIC
DISEASES
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OBJECTIVE: Numerous health outcomes research studies utilize
health plan administrative claims data to identify various disease
states. However, limited studies have evaluated the diagnostic
validity of these data sources for this purpose. This study was
conducted to evaluate the concordance between claims-based
identiﬁcation rules and medical records (MR) for coronary heart
disease (CHD), diabetes, and obesity. METHODS: A random
sample of patients on statin therapy from a West Coast health
plan with beneﬁt eligibility from January 1, 2002 to July 31,
2004 was identiﬁed via administrative claims data. All diseases
in these patients were identiﬁed using medical claims. MR were
utilized as the “gold-standard” and were abstracted by trained
MR reviewers using a standardized abstraction form over the 
eligibility date range. Sensitivity/speciﬁcity and kappa coefﬁ-
cients were calculated to examine the validity of claims and the
agreement between the two data sources, respectively. RESULTS:
A total of 531 patient MR were abstracted (15% CHD, 21%
diabetes, and 23% obesity via MR). Diabetes had the highest
sensitivity at 96%, followed by CHD and obesity at 78% and
18%, respectively. However, obesity demonstrated the highest
speciﬁcity (97%), with diabetes at 93%, and CHD at 87%.
Agreement between claims data and MR was good for diabetes
(kappa = 0.82, 95% CI = 0.77–0.88), moderate for CHD (kappa
= 0.53, 95% CI = 0.44–0.62), and poor for obesity (kappa =
0.20, 95% CI = 0.11–0.29). CONCLUSION: In our study,
administrative claims data were found to have acceptable 
sensitivity, speciﬁcity and agreement for diabetes and CHD.
These data suggest that claims data are a viable data source for
health outcomes research for those disease states. For less/poorly
coded conditions such as obesity, medical records (combined
with administrative claims data) may be a more valid data
source.
